Amgen, Inc. (NASDAQ:AMGN) announced a quarterly dividend on Wednesday, December 11th, RTT News reports. Stockholders of record on Friday, February 14th will be paid a dividend of 1.60 per share by the medical research company on Friday, March 6th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.73%. This is an increase from Amgen’s previous quarterly dividend of $1.45.
NASDAQ AMGN traded up $0.17 on Wednesday, reaching $234.01. The company had a trading volume of 1,754,093 shares, compared to its average volume of 2,841,155. The firm has a market capitalization of $138.90 billion, a PE ratio of 16.25, a P/E/G ratio of 2.21 and a beta of 1.12. Amgen has a 1 year low of $166.30 and a 1 year high of $235.80. The firm has a 50-day moving average of $222.02 and a 200-day moving average of $197.34. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.53 by $0.13. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. Amgen’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.69 EPS. As a group, sell-side analysts expect that Amgen will post 14.65 EPS for the current fiscal year.
A number of equities analysts have weighed in on the company. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a report on Monday, September 30th. William Blair restated a “hold” rating on shares of Amgen in a report on Friday, August 30th. Argus upped their price target on Amgen from $240.00 to $265.00 and gave the stock a “buy” rating in a report on Monday. Mizuho restated a “hold” rating and issued a $212.00 price target on shares of Amgen in a report on Sunday, September 29th. Finally, Goldman Sachs Group set a $243.00 price target on Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. Nine research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $225.44.
In other Amgen news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at approximately $1,166,230.85. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $193.58, for a total value of $387,160.00. Following the completion of the transaction, the director now directly owns 16,436 shares in the company, valued at $3,181,680.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,162 shares of company stock worth $4,601,190. 0.25% of the stock is currently owned by corporate insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: What is a Candlestick Chart?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.